Quality Control Sampling and Costs

1. Key takeaways

Honduras operates post-market quality control as a standing mechanism. Under Article 80 of Acuerdo No. 0631-ARSA-2023, ARSA may conduct quality control in its own laboratories at any stage of the regulatory cycle, either of its own motion or upon application; where it lacks the testing capability itself, it entrusts accredited external laboratories, domestic or foreign. Article 81: sampling follows the domestic or international standards in force, and two batches of samples must be taken — one for analysis (muestra para análisis) and one retention sample (muestra de retención) — each representative of the batch size. Article 82: all costs related to the testing (sample transport and execution of the testing) are borne by the licence holder, a term the provision defines across three categories of party: the product owner, the manufacturer, or the legal representative of the importer or distributor holding the sanitary authorisation for the device; the cost scope covers two items — sample transport and execution of testing — and the provision provides no refund mechanism.

2. Legal basis

The table below consolidates the quality-control powers of Articles 80 to 82 and the downstream provisions into which their results feed.

3. Expert insights

Insight 1: cost bearing is total and comes with no refund mechanism. Article 82 uses the phrase la totalidad de los costos — the entirety of the costs of sample transport and execution of testing — borne by the licence holder. The provision contains no arrangement for reimbursement when the result is satisfactory, and no cap either; sampling costs should therefore be treated as a routine post-market budget line, not an occasional expense.

Insight 2: two batches of samples means the sampled quantity doubles. Article 81 expressly requires one batch for analysis and one for retention, each proportionate to the batch size. For small-lot, high-unit-value implants or large equipment, the value of the retention sample alone can exceed the testing fee; pricing and inventory planning must account for this.

Insight 3: the external laboratory may be located abroad. Article 80 allows ARSA, where it lacks capability, to entrust un laboratorio externo ya sea nacional o extranjero debidamente acreditado — a duly accredited external laboratory, whether national or foreign. Once a foreign laboratory is entrusted, international sample transport and customs clearance times stack onto both cost and timeline.

Insight 4: sampling conclusions feed straight into the cancellation procedure. Article 88, item 2 makes the analysis report issued by a quality laboratory established by ARSA the basis for proving that composition does not conform or that quality and safety guarantees have been violated. Quality control is not an isolated compliance exercise: its output enters the cancellation chain of Article 88 directly, which is why every report deserves the same seriousness as a regulatory submission.

Insight 5: quality control can occur at any stage, not only post-market. The wording of Article 80 is en cualquier etapa del ciclo de regulación — at any stage of the regulatory cycle. Coverage therefore runs from review through the post-market phase, and a company’s inventory and retention-sample management (Article 11, items 3 and 4) must be ready to support sampling at any time.

4. Practical recommendations

• Put sampling costs into the annual budget: reserve the full amount for sample transport and execution of testing under Article 82, assuming no refund mechanism.
• Pre-plan retention samples for high-unit-value, small-lot products: confirm whether the retention stock counts as a value loss and reflect it in the pricing model.
• Keep inventory and retention samples available at all times: maintain precise stock and stock information under Article 11, items 3 and 4, so any batch can be located by number the moment a sampling notice arrives.
• Confirm who will execute the testing: ask ARSA whether an external laboratory has been entrusted for the current period and where it is located, and estimate transport and timeline accordingly.
• Assess the Article 88, item 2 risk in parallel with each test report: if the conclusion is unfavourable, start review and corrective action immediately to avoid entering the cancellation procedure.
• Analyse sampling results together with vigilance data: the same batch number may trigger both a quality-control conclusion and a 72-hour report under Article 18.

5. Verification checklist

• □ Sampling costs (transport plus testing) are in the annual budget with no refund assumption
• □ Retention-sample value loss for high-unit-value products is built into the pricing model
• □ Batch-level inventory and stock information can be retrieved at any time
• □ The current testing executor (in-house or external laboratory) has been confirmed
• □ A review and corrective-action plan for Article 88, item 2 situations is in place
• □ A data linkage between sampling results and vigilance reports has been established

Related reading: [Article 48 — Advertising: the seven controls and four prohibitions of Article 77](/honduras-medical-device-registration/advertising-rules-article-77/) | [Article 46 — Semiannual report and vigilance liaison](/honduras-medical-device-registration/semiannual-report-and-vigilance-liaison/) | [Article 26 — Labelling: primary and supplementary labels under Article 84](/honduras-medical-device-registration/labelling-primary-and-complementary/)

Regulatory information verified as of October 29, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Honduran market. Our team manages Secretariat of Health (SESAL) registration applications, prepares Spanish-language dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com